MGUS stands for monoclonal gammopathy of undetermined significance. It’s a condition where a small group of abnormal cells in your bone marrow produces an unusual protein that shows up in your blood. MGUS itself isn’t cancer, but it requires long-term monitoring because it carries a small, ongoing risk of developing into a blood cancer like multiple myeloma.
What Happens in Your Body
Your immune system normally produces a wide variety of antibodies, each made by a different type of plasma cell in your bone marrow. In MGUS, a single clone of plasma cells multiplies more than it should and churns out one specific antibody, called a monoclonal protein (or M protein). This protein serves no useful immune function. It just accumulates in your blood, where it can be detected on routine lab work.
The reason this single clone expands in what appears to be a non-cancerous way is unknown in most cases. About half of cases show a specific genetic rearrangement in the antibody-producing region of chromosome 14, which is thought to help sustain the clonal growth. Most cases involve IgG or IgA type proteins, while roughly 15 to 20 percent involve IgM proteins, which arise from a slightly different cell type.
How Common MGUS Is
MGUS is surprisingly prevalent, especially as people age. In a large study of over 21,000 residents in Olmsted County, Minnesota, 3.2% of people aged 50 or older had MGUS. The rate climbed to 5.3% in people over 70, and nearly 9% in men older than 85. Men are affected more often than women overall, at 4.0% versus 2.7%.
Many people with MGUS never know they have it until an abnormal protein is spotted during blood tests ordered for something else entirely.
How MGUS Is Diagnosed
A diagnosis of MGUS requires meeting three criteria simultaneously:
- M protein level below 3 g/dL in the blood
- Less than 10% clonal plasma cells in the bone marrow
- No signs of organ damage from the abnormal protein
That last point is critical. Doctors specifically look for the absence of four problems, remembered by the acronym CRAB: elevated calcium in the blood, renal (kidney) failure, anemia, and bone lesions. If any of those are present and linked to the abnormal protein, the diagnosis shifts toward something more serious like multiple myeloma.
MGUS vs. Smoldering Myeloma
MGUS sits at one end of a spectrum. A step further along is smoldering multiple myeloma (SMM), which is also not yet active cancer but represents a higher burden of abnormal cells. The numbers tell the story clearly: in studies comparing the two, patients with smoldering myeloma had a median M protein level of 2.0 g/dL compared to 1.2 g/dL in MGUS, and their bone marrow plasma cell burden was about 20% versus 9%. Hemoglobin levels also tended to be lower in smoldering myeloma patients (12.4 g/dL versus 13.8 g/dL), hinting at early effects on normal blood cell production.
The distinction matters because smoldering myeloma carries a significantly higher risk of progressing to active cancer and is monitored more closely.
Risk of Progressing to Cancer
On average, about 1% of people with MGUS go on to develop multiple myeloma or a related blood cancer each year. That means after 10 years, roughly 10% of people diagnosed with MGUS will have progressed. The risk doesn’t go away over time; it persists for as long as you live.
Not everyone faces the same level of risk. A widely used model from the Mayo Clinic stratifies patients into four risk categories based on three factors: the size of the M protein (whether it’s above or below 1.5 g/dL), the type of immunoglobulin (IgG carries lower risk than other types), and the ratio of free light chains in the blood (a measure of how imbalanced antibody production has become). Having none of these risk factors puts you in a low-risk group, while having all three places you in a high-risk group with a meaningfully greater chance of progression.
What Monitoring Looks Like
Because MGUS requires no treatment but does carry ongoing risk, the standard approach is regular blood work to track your M protein level and other markers over time. For low-risk patients, this typically means a check-in with lab work every six to twelve months initially, then potentially less frequently if levels remain stable. Higher-risk patients are followed more closely.
The things your doctor watches for include a rising M protein level, a drop in your normal immunoglobulin levels, changes in your blood counts, or the emergence of any CRAB symptoms. A sudden increase in any of these markers can signal that MGUS is evolving into something that needs treatment.
When MGUS Causes Problems on Its Own
The word “undetermined” in the name implies MGUS is always harmless, but that’s not entirely accurate. In some cases, the abnormal protein itself causes damage to organs even though the underlying clone of cells remains small and non-cancerous. This has led doctors to recognize a related concept called monoclonal gammopathy of clinical significance, or MGCS.
The most commonly affected organs are the kidneys, nerves, and skin. The abnormal protein can deposit in kidney tissue and impair filtration, cause nerve damage leading to numbness or weakness in the hands and feet, or trigger skin conditions. Some of these complications are serious and even life-threatening despite the fact that the clone producing the protein hasn’t become a full-blown cancer. When MGCS is identified, treatment targets the small clone of cells producing the harmful protein, even though it wouldn’t otherwise meet the threshold for cancer treatment.
This is an important distinction: if you have MGUS and develop unexplained kidney problems, nerve symptoms, or unusual skin changes, the M protein itself could be the cause, not just a bystander.